Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin
Abstract
Latent autoimmune diabetes in youth (LADY) is a poorly characterized form of autoimmune diabetes with onset between 8 and 29 years of age and with slow progression toward insulin dependence, similarly to latent autoimmune diabetes of the adult (LADA), which leads to diagnostic difficulties and possibly to therapeutic implications. In this case series, we discuss two cases of juvenile- and young adult-onset autoimmune diabetes with very low insulin need at least after diagnosis and the efficacy of treatment with semaglutide. In case 1, a 20-year-old woman with obesity (31.8 kg/m2) with a non-ketoacidotic onset of diabetes was initially put on metformin and basal insulin. Previous ultrasound of the abdomen showed a hyperechogenic liver pattern. Tests showed high-titer multiple diabetes-related autoantibodies positivity, but still detectable C-peptide levels; thus, metformin was stopped and semaglutide was started. After 12 months, the patient still continues oral semaglutide and basal insulin, with detectable C-peptide, and has experienced significant weight loss (-20 kg) and resolution of liver steatosis. In case 2, a 13-year-old girl was diagnosed with autoimmune diabetes, with tests showing high-titer multiple diabetes-related autoantibodies positivity. She was initially put on multiple daily insulin injections (MDI). After almost 2 years, presenting to our care with still detectable C-peptide, we decided to stop meal-time insulin and to start oral semaglutide. After 15…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.